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Abstract 1 
Purpose: Mouse models are useful for glaucoma research, but it is unclear 2 
whether intraocular pressure (IOP) regulation in mice operates through 3 
mechanisms similar to those in humans. Our goal was to determine whether 4 
pharmacological compounds that affect conventional outflow facility in human 5 
eyes exert similar effects in C57BL/6 mice. 6 
Methods: A computerized perfusion system was used to measure conventional 7 
outflow facility in enucleated mouse eyes ex vivo. Paired eyes were perfused 8 
sequentially, either immediately after enucleation or after 3 hrs storage at 4°C. 9 
Three groups of experiments examined: (i) sphingosine 1-phosphate (S1P); (ii) 10 
S1P with antagonists to S1P1 and S1P2 receptors; and (iii) the prostanoid EP4 11 
agonist 3,7-dithia PGE1. We also examined whether a 24 hrs post-mortem delay 12 
affected the response to 3,7-dithia PGE1.  13 
Results: S1P decreased facility by 39%, and was almost completely blocked by 14 
an S1P2, but not S1P1, antagonist. S1P2 antagonist alone increased facility 15 
nearly 2-fold. 3,7-dithia PGE1 increased facility by 106% within 3 hrs post-16 
mortem. By 24 hrs post-mortem, the facility increase caused by 3,7-dithia PGE1 17 
was reduced 3-fold, yet remained statistically detectable. 18 
Conclusions: C57BL/6 mice show opposing effects of S1P2 and EP4 receptors 19 
on conventional outflow facility, as observed in human eyes. Pharmacological 20 
effects on facility are detectable up to 24 hrs post-mortem in enucleated mouse 21 
eyes. Mice are suitable models to examine the pharmacology of S1P and EP4 22 
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receptor stimulation on IOP regulation as occurs within the conventional outflow 1 
pathway of human eyes, and are promising for studying other aspects of 2 
aqueous outflow dynamics.3 
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Introduction 1 
Mice provide important models for glaucoma research, due to their genetic 2 
malleability and the extensive catalog of molecular tools that may be exploited to 3 
investigate disease mechanisms1. While most glaucoma research involving mice 4 
has focused on the effect of elevated intraocular pressure (IOP) on the optic 5 
nerve, a small but growing community2-13 has begun using mice to investigate the 6 
physiology of aqueous humor outflow, with the aim to better understand the 7 
mechanisms of IOP regulation. In fact, recent data show that the morphology and 8 
behavior of the murine conventional outflow pathway is more similar in some 9 
ways to humans than are non-human primates (e.g., like humans14, mice do not 10 
appear to exhibit ‘washout’11, while ‘washout’ is observed in monkeys14). 11 
Notwithstanding the utility of mouse models, it remains an open question whether 12 
mice are appropriate models for IOP regulation at the level of the conventional 13 
outflow pathway as occurs within human eyes. 14 
Compounds that affect IOP in humans tend to have similar effects in mice, 15 
however the response is not always through the same mechanisms, as noted 16 
previously10. For example, latanoprost lowers IOP4,10,15-17 and increases 17 
conventional outflow facility4,10 in mice without any detectible effects on 18 
unconventional outflow4,10, unlike the response in human eyes where latanoprost 19 
increases both conventional18 and unconventional outflow19. This suggests that 20 
the physiology and pharmacology of aqueous humor outflow may differ 21 
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substantially between mice and humans, and should be carefully examined 1 
before accepting the mouse as a reliable model for human IOP regulation.  2 
The goal of this project was to determine whether pharmacological 3 
compounds that are known to affect conventional outflow facility in human eyes 4 
exert similar effects on conventional outflow facility in C57BL/6 mice. We 5 
specifically examined the facility response to two G-protein coupled receptor 6 
agonists, sphingosine 1-phosphate (S1P) and the prostanoid EP4 agonist 3,7-7 
dithia PGE1, that respectively decrease20 and increase21 outflow facility in human 8 
eyes. By comparing the facility response measured in enucleated murine eyes 9 
against previous reports in enucleated human eyes20,21, we aimed to determine 10 
whether C57BL/6 mice mimic aspects of human conventional outflow pathway 11 
pharmacology, which would identify this strain as a promising animal model for 12 
S1P and EP4-based regulation of IOP as occurs within human eyes. We also 13 
examined whether the pharmacological response is affected by prolonged post-14 
mortem times, which is an important consideration for using the mouse model as 15 
a research tool when doing ex vivo perfusions.16 
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Methods 1 
All experiments were performed using ex vivo tissue and were done in 2 
compliance with the ARVO Statement for the Use of Animals in Ophthalmic and 3 
Vision Research. 4 
Ex Vivo Mouse Eye Perfusion   5 
C57BL/6 mice of either sex, aged 8-15 weeks, were killed by cervical 6 
dislocation. Eyes were enucleated within 10 minutes of death and perfused 7 
immediately or stored in phosphate buffered saline (PBS) at 4°C for 2-3 hours. 8 
For perfusion, each eye was mounted on a single well of a 96-well Stripwell plate 9 
(Corning) using cyanoacrylate glue to affix the extraocular muscles to the plastic 10 
sidewalls of a well. Special attention was given to maintain hydration throughout 11 
the experiment by covering the eye with tissue paper that was kept moist by 12 
regular drops of PBS. The perfusion solution was Dulbecco’s PBS including 13 
divalent cations and 5.5 mM glucose (referred to as “DBG”) filtered through a 14 
0.22 µm filter before use. All perfusions were done at room temperature, with a 15 
post hoc correction to account for the viscosity difference between room and 16 
physiologic temperature11,22. 17 
Our perfusion method follows previously described techniques11. Briefly, a 18 
33-gauge needle was used to cannulate the anterior chamber under a 19 
stereomicroscope using a micromanipulator. The needle was connected via rigid 20 
pressure tubing to a glass syringe (25 µL, Hamilton GasTight) placed on the rack 21 
of a motorized syringe pump (Pump33; Harvard Apparatus) under computer 22 
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control. A pressure transducer (142PC01G, Honeywell) monitored IOP through a 1 
three-way connector placed in the perfusion line. Custom written LabVIEW 2 
software23 was used to automatically vary the flow rate from the syringe pump to 3 
maintain the eye at a user-defined IOP. Eyes were perfused at sequential 4 
pressure steps of 4, 8, 15, and 25 mmHg; we refer to this as our “standard 5 
perfusion regimen.” Eyes were typically perfused for 20 minutes at each pressure 6 
step to obtain at least 10 minutes of stable perfusion data, and an average stable 7 
flow rate was calculated at each pressure step (Fig. 1). Data were considered 8 
acceptable if a stable flow rate was achieved in at least 3 of the 4 pressure steps. 9 
Based on this criterion, we rejected 12 eyes out of 88 valid perfusions. Selected 10 
eyes were fixed by removing the perfusion needle and immediately immersing 11 
the eye in 4% paraformaldehyde (PFA) in isotonic saline for 1 hour, followed by 12 
long-term storage in 0.1% PFA. For histology, eyes were processed for paraffin 13 
embedding, sectioned and stained using hematoxylin and eosin. 14 
Outflow Facility Analysis 15 
We calculated a pressure-dependent or “conventional outflow facility” (C) 16 
by fitting our pressure-flow rate data to the modified Goldmann equation24:  17 
     (Eq. 1) 18 
where F represents the stable flow rate at each corresponding IOP. Fu in 19 
Equation 1 is usually taken as an estimate of the pressure-independent or 20 
“unconventional” outflow rate11. Equation 1 is valid only when (i) episcleral 21 
venous pressure is zero (appropriate for enucleated eyes); (ii) F reaches 22 
 
F = C IOP( )+ Fu
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equilibrium at each value of IOP; and (iii) C and Fu are independent of IOP. The 1 
values of C and Fu are defined as the slope and intercept, respectively, of the 2 
best-fit linear regression to our measured F versus IOP data (Fig. 1B). In 3 
principle, C would be consistent with values obtained from a 2-level 4 
perfusion3,4,6,7,25, except that the additional pressure steps give a much stronger 5 
confidence for estimating C8,10. Both C and Fu were multiplied by a factor of 1.38 6 
to account for viscosity differences between physiologic and room temperatures, 7 
as previously described11,22. 8 
Experimental Design 9 
 We conducted three sets of perfusion experiments to measure how 10 
conventional outflow facility in the mouse eye responded to receptor-mediated 11 
compounds known to affect conventional outflow in human eyes. Experiments 12 
used paired eyes (treated vs. untreated contralateral controls), except for cases 13 
where data from one eye were rejected based on the stability criterion described 14 
above. Paired eyes were perfused sequentially (one eye immediately after 15 
enucleation, the contralateral eye 2-3 hrs after enucleation), where we 16 
randomised whether the control or experimental eye was perfused first. We also 17 
examined whether prolonged post-mortem time (24 hrs storage after enucleation 18 
at 4°C) affected the pharmacologic response between paired eyes. 19 
In the first set of experiments (Group A), we examined the effect of 20 
sphingosine 1-phosphate (S1P), a bioactive lipid that decreases outflow facility 21 
by 31% in porcine eyes26 and 36% in human eyes20. Experimental eyes were 22 
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perfused with 5 µM S1P in DBG containing fatty acid free bovine serum albumin 1 
(FAF-BSA; 2 mg/mL; Sigma-Aldrich A8806) and 17 µM sodium hydroxide 2 
(NaOH), while control eyes received DBG and FAF-BSA alone without S1P or 3 
NaOH. Independent studies demonstrated that 17 µM NaOH had a negligible 4 
effect on the pH of DBG (7.137±0.031 vs. 7.107±0.012 for Dulbecco’s PBS with 5 
or without 17 µM NaOH, respectively, N = 3 independent trials each, p = 0.23; 6 
Student’s t-test), and therefore NaOH was not included in the control solution. 7 
S1P (CAS 26993-30-6 from Sigma-Aldrich, UK) was dissolved from powder into 8 
10 mM NaOH in water to give a 3 mM S1P stock solution that was stored 9 
at -20°C. Prior to cannulation, each needle was backfilled from the tip with 10 
150 µL of the appropriate perfusion solution, a volume sufficient to last several 11 
hours even at the highest measured flow rates (~0.3 µL/min). The experimental 12 
eye was pre-treated with S1P-containing solution from a reservoir at 8 mmHg for 13 
45 minutes to expose the outflow pathway to the drug prior to the start of the 14 
standard perfusion regimen. Control eyes were perfused from a reservoir for the 15 
same time with solution without S1P. Data from 14 individual eyes (8 S1P-treated 16 
and 6 controls, containing 6 pairs) passed the stability criterion and were 17 
included in Group A. 18 
The aim of the second set of experiments (Group B) was to investigate the 19 
role of S1P1 and S1P2 receptors in mediating the S1P response. Following a 20 
previous study in human eyes27, we used W146 (Avanti Polar Lipids) or JTE-013 21 
(Cayman Chemical) that are selective antagonists to S1P1 or S1P2 receptors, 22 
respectively. W146 was dissolved in water as a 1 mM stock solution containing 23 
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10.6 mM cyclodextrin and 100 mM sodium carbonate (Na2CO3) as vehicle, and 1 
was stored at -20°C. JTE-013 was dissolved in DMSO as a 1 mM stock solution 2 
and stored at -20°C. Experimental eyes were pre-treated with antagonist and 3 
S1P-containing solution (45 minutes at 8 mmHg from a reservoir) followed by 4 
perfusion with the same solution over the standard perfusion regimen. For W146-5 
treated experimental eyes, the perfusion solution contained 5 µM W146 in DBG + 6 
5 µM S1P + 2 mg/mL FAF-BSA + 17 µM NaOH + 53 µM cyclodextrin + 500 µM 7 
Na2CO3. For JTE-treated experimental eyes, the perfusion solution contained 8 
5 µM JTE-013 in DBG + 5 µM S1P + 2 mg/mL FAF-BSA + 17 µM NaOH + 9 
70 mM DMSO. Antagonist concentrations (5 µM) were chosen to be consistent 10 
with concentrations used in prior perfusion studies with porcine and human 11 
eyes27 and were several fold larger than reported IC50 values (0.83 µM for 12 
W14628 and 1.0 µM for JTE-01327). Control eyes were perfused with 5 µM S1P in 13 
DBG + 2 mg/mL FAF-BSA + 17 µM NaOH, without antagonist, cyclodextrin, 14 
Na2CO3 or DMSO vehicle and without pre-treatment. Data from 8 eyes were 15 
included in the JTE study (4 JTE-treated and 4 controls, containing 4 pairs), and 16 
data from 7 eyes were included in the W146 study (3 W146-treated and 4 17 
controls, containing 3 pairs). 18 
To account for possible vehicle effects caused by cyclodextrin, Na2CO3 or 19 
DMSO, we repeated the W146 and JTE-013 antagonist studies using the same 20 
vehicle formulations in the control eyes. For these studies, the control eyes from 21 
the W146 study received 5 µM S1P in DBG + 2 mg/mL FAF-BSA + 17 µM NaOH 22 
+ 53 µM cyclodextrin + 500 µM Na2CO3, while the experimental eyes from the 23 
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W146 study received the same solution with 5 µM W146. The control eyes from 1 
the JTE study received 5 µM S1P in DBG + 2 mg/mL FAF-BSA + 17 µM NaOH, 2 
+ 70 mM DMSO, while the experimental eyes from the JTE study received the 3 
same solution with 5 µM JTE-013. Both control and experimental eyes were 4 
pretreated with perfusion solution for 45 minutes at 8 mmHg from a reservoir 5 
prior to starting the standard perfusion regimen. Data from 7 eyes were included 6 
in the JTE vehicle-controlled study (3 JTE-treated and 4 controls, containing 3 7 
pairs), and data from 7 eyes were included in the W146 vehicle-controlled study 8 
(4 W146-treated and 3 controls, containing 3 pairs). 9 
In an additional 10 eyes (3 pairs and 4 unpaired eyes), we examined the 10 
influence of JTE antagonist alone on outflow facility. For these studies, 11 
experimental eyes were perfused with 5 µM JTE-013 + 70 mM DMSO in DBG 12 
without FAF-BSA (N = 5 eyes), while the control eyes were perfused with DBG 13 
alone without JTE, DMSO, or FAF-BSA (N = 5) using the standard perfusion 14 
regimen. Because 70 mM DMSO was found not to affect the facility response in 15 
JTE-treated eyes in the presence of S1P (see below), it was not included in the 16 
perfusion solution for the control eyes.  17 
In the third set of experiments (Group C), we examined the influence of 18 
prostaglandin EP4 receptor activation on conventional outflow in the mouse eye 19 
by perfusion with 3,7-dithia PGE1, a highly selective PG-EP4 receptor agonist29 20 
that increases conventional outflow facility in human21 and monkey eyes30 21 
without affecting unconventional outflow. 3,7-dithia PGE1 was dissolved in 22 
ethanol as a 10 mM stock solution and stored at -20°C. Experimental eyes were 23 
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pre-treated (45 min at 8 mmHg from a reservoir) and perfused with 10 nM 3,7-1 
dithia PGE1 in DBG + 17 µM ethanol without FAF-BSA. Control eyes were 2 
perfused with DBG alone without ethanol or pre-treatment. Ethanol was not 3 
included in the perfusion solution of the control eyes because 17 µM ethanol is 4 
approximately 1000-fold smaller than typical millimolar concentrations shown to 5 
have minimal effects on cultured cells31,32. Data examining the effects of 3,7-6 
dithia PGE1 included 13 eyes (7 treated and 6 untreated control eyes, containing 7 
4 pairs). 8 
In an additional 10 eyes (including 4 pairs and 2 unpaired eyes), we 9 
examined whether the response to 3,7-dithia PGE1 was affected by post-mortem 10 
time. For these studies, eyes were enucleated and stored for 24 hrs at 4°C in 11 
Dulbecco’s modified Eagle’s medium (DMEM) and then perfused with 10 nM 3,7-12 
dithia PGE1 in DBG + 17 µM ethanol (N = 6) or with DBG + 17 µM ethanol 13 
(N = 4) using the standard perfusion regimen. We chose to examine the post-14 
mortem facility response to 3,7-dithia PGE1, rather than to S1P, for two reasons. 15 
First, 3,7-dithia PGE1 causes a larger change in outflow facility compared to S1P 16 
(e.g., 69% increase following 3,7-dithia PGE121 versus 36% decrease following 17 
S1P20 in human eyes, respectively), and therefore 3,7-dithia PGE1 would provide 18 
a more conservative test to detect smaller differences in facility that might occur 19 
with prolonged post-mortem times. Second, 3,7-dithia PGE1 is an exogenous 20 
compound (unlike S1P) and is therefore more representative of potential 21 
candidate drugs that may affect conventional outflow. Therefore, by looking at 22 
how the facility response to 3,7-dithia PGE1 changes with post-mortem time, we 23 
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can gain some insight into how post-mortem time may affect the interpretation of 1 
drug efficacy in perfusion experiments (that often incorporate eyes with post-2 
mortem times up to 24 hours or use transgenic models where eyes are shipped 3 
overnight between laboratories). 4 
Statistical Methods 5 
All experiments included in this study contained some portion of unpaired 6 
eyes caused by one eye of a pair failing to pass the stability criterion. To analyze 7 
our data, we performed two statistical analyses: (i) a Welch’s t-test that included 8 
the full set of eyes (accounting for unequal sample sizes); and (ii) a paired, 2-9 
tailed Student’s t-test that included only the subset of paired contralateral eyes. 10 
Wherever appropriate, we indicate whether a paired Student’s t-test or a Welch’s 11 
t-test was performed. The statistical significance threshold was taken to be a p-12 
value of 0.05. 13 
All facility values quoted in the text were temperature-corrected to account 14 
for viscosity differences, as described above. Figures showing flow rate data, 15 
however, were not corrected and represent the true flow rate output from the 16 
syringe pump. 17 
18 
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Results 1 
Group A, S1P Decreases Conventional Outflow Facility in Mice 2 
Perfusion with 5 µM S1P caused a reduction in flow rate at each perfusion 3 
pressure (Fig. 1A). Compiling data from all eyes revealed a linear relationship 4 
between flow rate and IOP (Fig. 1B), consistent with the modified Goldmann 5 
equation (Eq. 1). In response to S1P, conventional outflow facility (C; slope of the 6 
linear regression) decreased by 38.9 ± 24.2% (mean ± SD; p = 0.029, paired 7 
Student’s t-test, N = 6 pairs) compared to paired contralateral eyes perfused 8 
without S1P. After temperature correction, conventional outflow facility was 9 
0.0125 ± 0.0037 and 0.0073 ± 0.0035 µL/min/mmHg for control and S1P-treated 10 
eyes (p = 0.024, Welch’s t-test, N = 8 S1P-treated eyes and 6 controls), 11 
respectively. We observed no statistical difference in the intercept of the linear 12 
regression in response to S1P in either paired (p = 0.71) or unpaired analyses 13 
(p = 0.56, Welch’s t-test). We observed no obvious differences in the morphology 14 
of the trabecular meshwork or Schlemm’s canal following treatment with S1P 15 
(Fig. 2).  16 
Group B, The S1P2 Receptor Mediates the S1P Response 17 
To determine which receptor mediates the S1P response measured in 18 
Group A, we perfused contralateral eyes with either S1P or S1P in combination 19 
with either an antagonist to the S1P2 receptor (5 µM JTE-013; Fig. 3A) or an 20 
antagonist to the S1P1 receptor (5 µM W146; Fig. 3B). In eyes treated with S1P 21 
without antagonist, the conventional outflow facility was 0.0074 ± 0.0034 22 
µL/min/mmHg (N = 15 control eyes from the JTE and W146 experiments; 23 
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temperature-corrected), which was similar to the conventional facility measured 1 
for S1P-treated eyes in Group A. There was no difference in conventional outflow 2 
facility caused by vehicle, either for 70 mM DMSO (0.0072 ± 0.0052 vs. 0.0068 3 
± 0.0017 µL/min/mmHg in S1P-treated control eyes from the JTE studies with or 4 
without DMSO, respectively; temperature-corrected; p = 0.90, Welch’s t-test, N = 5 
4 for each group) or for 53 µM cyclodextrin and 500 µM Na2CO3 6 
(0.0078 ± 0.0040 vs. 0.0079 ± 0.0035 µL/min/mmHg in S1P-treated control eyes 7 
from the W146 study with or without cyclodextrin + Na2CO3, respectively; 8 
temperature-corrected; p = 0.97, Welch’s t-test, N = 3 or 4, respectively). For this 9 
reason, we compiled all data with and without vehicle control from the W146 or 10 
JTE perfusions with S1P. The compiled data shown in Figures 3A and 3B include 11 
15 eyes for the JTE antagonist studies (8 controls + 7 experimentals, including 7 12 
pairs) and 14 eyes for the W146 antagonist studies (7 controls + 7 experimentals, 13 
including 6 pairs). 14 
 In eyes perfused with both S1P and JTE, the temperature-corrected 15 
conventional facility was 0.0133 ± 0.0019 µL/min/mmHg, nearly 2-fold larger than 16 
eyes treated with S1P without antagonist (0.0070 ± 0.0036 µL/min/mmHg; p = 17 
0.0012, Welch’s t-test , N = 8 S1P vs. 7 S1P + JTE,) and similar to the 18 
conventional facility of control eyes from Group A. In contrast, conventional 19 
facility was unchanged between eyes perfused with S1P or S1P and W146 20 
(0.0079 ± 0.0034 vs. 0.0094 ± 0.0032 µL/min/mmHg; temperature-corrected; p = 21 
0.41, Welch’s t-test, N = 7 S1P vs. 7 S1P + W146; β = 0.145, α = 0.05, assuming 22 
the facility values for S1P-treated and untreated eyes from Group A with N = 7 for 23 
Page 16 of 35 
 
each group). These data demonstrate that JTE largely blocks the facility-reducing 1 
effect of S1P, while W146 has little effect, suggesting that the S1P2 receptor, and 2 
not the S1P1 receptor, is principally responsible for mediating the S1P response 3 
in C57BL/6 mice. We did not observe significant effects of JTE or W146 in the 4 
presence of S1P on the intercept of the pressure-flow relationship (p ≥ 0.27). 5 
In eyes perfused with 5 µM JTE without S1P, temperature-corrected 6 
conventional facility was nearly 2-fold greater than in untreated control eyes (Fig. 7 
3C), increasing from 0.0096 ± 0.0026 to 0.0194 ± 0.0056 µL/min/mmHg 8 
(p = 0.017; N = 5 control and N = 5 JTE-treated eyes, Welch’s t-test). There was 9 
no significant difference in the intercept of the pressure-flow relationship between 10 
JTE-treated and untreated eyes (p = 0.19). These data suggest that endogenous 11 
S1P signaling may be regulating conventional outflow facility in the mouse 12 
trabecular meshwork, which can be blocked by S1P2 receptor antagonist JTE-13 
013. 14 
Group C, EP4 Receptor Agonist Increases Conventional Outflow Facility in 15 
Mice 16 
We measured a two-fold increase in conventional outflow facility following 17 
perfusion with 10 nM 3,7-dithia PGE1 (Fig. 4A), with the temperature-corrected 18 
facility increasing from 0.0062 ± 0.0005 to 0.0131 ± 0.0024 µL/min/mmHg 19 
(p = 0.0003; Welch’s t-test; N = 6 or 7 for untreated eyes or eyes treated with 3,7-20 
dithia PGE1, respectively). Considering only paired eyes, the conventional facility 21 
increased by 105.8 ± 48.4% following 3,7-dithia PGE1 treatment compared to 22 
untreated contralateral eyes (p = 0.02; paired Student’s t-test, N = 4 pairs). In 23 
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contrast, 3,7-dithia PGE1 inconsistently affected the intercept of the pressure-flow 1 
relationship. More specifically, while we observed a statistically detectable 2 
decrease in the intercept between treated and untreated groups using unpaired 3 
analysis (p = 0.04), we observed no difference using paired analysis (p = 0.31). 4 
After 24 hrs post-enucleation and storage at 4°C in DMEM, eyes appeared 5 
well preserved with clear corneas and constricted pupils. In contrast, eyes stored 6 
for the same period in PBS at 4°C appeared “mushy” with cloudy corneas and 7 
dilated pupils. Following 24 hr storage in DMEM, conventional outflow facility in 8 
eyes perfused with 3,7-dithia PGE1 was 0.0128 ± 0.0034 µL/min/mmHg (N = 6 9 
eyes; Fig. 4B), which was significantly larger (p = 0.037, Welch’s t-test) than the 10 
baseline facility of untreated eyes (0.0087 ± 0.0014 µL/min/mmHg, N = 4 eyes) 11 
by unpaired analysis. When considering only paired eyes, the relative facility 12 
increase following 3,7-dithia PGE1 was nearly 3-fold smaller after 24 hrs 13 
(38.1 ± 34.5%; N = 4 pairs) versus after 3 hrs (see above) and failed to achieve 14 
statistical significance (p = 0.126, paired Student’s t-test). Similarly, after 24 hrs 15 
for pressures of 8 mmHg and above, there was a tendency for 3,7-dithia PGE1 to 16 
increase the flow rate, but even at 25 mmHg the flow rate increase failed to 17 
achieve statistical significance (p = 0.10). This is in contrast to eyes perfused 18 
within 3 hrs post-mortem, when 3,7-dithia PGE1 caused a statistically significant 19 
increase in flow rate for all pressures of 8 mmHg or larger (p < 0.05). This 20 
suggests that while the facility-increasing effect of 3,7-dithia PGE1 was present 21 
24 hrs after enucleation, the effect was subtle and detectable only when flow 22 
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rates were measured over several perfusion pressures and linear regression 1 
analysis was used to calculate the slope of the flow rate-pressure relationship. 2 
Discussion 3 
This study demonstrates that C57BL/6 mouse eyes respond to S1P and 4 
EP4 agonist in a similar manner as that previously reported for human eyes. 5 
Specifically, S1P decreased murine outflow facility by 39%, which was nearly 6 
identical to the 36% decrease previously reported in human eyes20. The 7 
prostanoid EP4 agonist, 3,7-dithia PGE1, caused a facility increase of 106% in 8 
mice, which was somewhat larger than the 69% increase observed in human 9 
eyes21. Quantitative differences aside, the similarity in qualitative response 10 
between species suggests that similar pharmacological signaling mechanisms 11 
underlie the facility response to S1P and 3,7-dithia PGE1 between C57BL/6 mice 12 
and human eyes. 13 
S1P is known to bind to one of five G protein-coupled receptors (S1P1-5) 14 
each of which exhibit different downstream signaling events and are differentially 15 
regulated in different tissues33. S1P rapidly decreases outflow facility20,26, and 16 
lysophospholipids similar to S1P are found in aqueous humor34, possibly acting 17 
as endogenous regulators of outflow facility35.  In C57BL/6 mice, we detected 18 
expression of S1P1 and negligible levels of S1P2 and S1P3 in Schlemm’s canal 19 
endothelium by in situ confocal immunofluorescence (Supplemental Figure 1). 20 
The relative absence of S1P2 and S1P3 labeling could be attributed to reduced 21 
antibody sensitivity compared to prior studies by our group20 that reported 22 
relatively low levels of S1P2 and S1P3 expression, compared to S1P1, by human 23 
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Schlemm’s canal cells in situ. Despite the seemingly low levels of S1P2 1 
expression, the facility-decreasing effect of S1P in mice was almost completely 2 
abolished by JTE-013, an antagonist to the S1P2 receptor, but not by W146, an 3 
antagonist to the S1P1 receptor. Similar effects were observed in human eyes27, 4 
where JTE-013 blocked facility reduction as well as phosphorylated myosin light 5 
chain (pMLC) in response to S1P, while no blocking effect on pMLC was 6 
observed in the presence of either W146 or VPC23019 (a dual antagonist to 7 
S1P1 and S1P3). Perfusion with JTE-013 alone increased conventional outflow by 8 
two-fold in C57BL/6 mice, yielding a conventional outflow facility (0.0194 ± 9 
0.0056 µL/min/mmHg, N = 5) that was larger than that measured in either 10 
untreated eyes (0.0125 ± 0.0037 µL/min/mmHg, N = 6, from Group A; p = 0.056, 11 
Welch’s t-test) or eyes perfused with 3,7-dithia PGE1 (0.0131 ± 0.0024 12 
µL/min/mmHg, N = 7, from Group C; p = 0.063, Welch’s t test). These data 13 
strongly implicate the S1P2 receptor as a key mediator of the facility-regulating 14 
effect of S1P and suggest an endogenous concentration of S1P within the 15 
trabecular meshwork. It should be noted however, that the selectivity of JTE-013 16 
to the S1P2 receptor has been recently called into question36,37 based on data 17 
reporting an effect of JTE-013 in S1P2 knock-out mice38. Therefore, future 18 
studies should account for potential off-target effects, possibly by incorporating 19 
genetically altered mice to better understand the underlying mechanisms by 20 
which S1P regulates outflow facility.  21 
3,7-dithia PGE1 was the first selective agonist developed against the EP4 22 
receptor29 and has been shown to lower IOP by nearly 40% in cynomolgus 23 
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monkeys by increasing trabecular outflow facility without affecting uveoscleral 1 
outflow30. Similarly, 3,7-dithia PGE1 increases conventional outflow facility in 2 
post-mortem human eyes by 69%21, consistent with the expression of PG-EP4 in 3 
human trabecular meshwork and Schlemm’s canal in situ21,39. At 10 nM 4 
concentration, however, the effect of 3,7-dithia PGE1 appears to be selective for 5 
Schlemm’s canal cells, with no observed effect on trabecular meshwork cells, 6 
based on cell culture assays of cAMP accumulation following PG-EP4 receptor 7 
activation21. Compared to humans, our data show that 3,7-dithia PGE1 had a 8 
nearly two-fold larger effect in C57BL/6 mice (106% vs. 69%21), and expression 9 
of PG-EP4 has already been demonstrated within the trabecular meshwork and 10 
Schlemm’s canal in other strains of mice40.  The larger facility increase in mice 11 
may reflect differences in EP4 sensitivity between species or with age, or it may 12 
be due to improved preservation of mouse tissue due to shorter post-mortem 13 
times. Alternatively, because mice have a more prominent Schlemm’s canal with 14 
only 2-4 trabecular beams compared to 12-20 in humans41, mice may be 15 
predisposed to exhibit a more robust facility response to compounds such as 3,7-16 
dithia PGE1 that preferentially affect Schlemm’s canal (see above), as opposed 17 
to trabecular meshwork, cells21. Regardless, the robust facility-increasing 18 
response following 3,7-dithia PGE1 strongly suggests that C57BL/6 mice are a 19 
good pharmacological model for investigating the contribution of EP4, and 20 
possibly other prostanoid receptors, in the regulation of conventional outflow. 21 
This may be particularly interesting given that prostaglandin PGE2, a natural 22 
ligand for EP4 receptors42, is present within aqueous humor at reduced 23 
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concentrations in eyes from patients with primary open-angle and steroid-1 
induced glaucoma43. 2 
Post hoc comparison of facility data revealed that conventional outflow 3 
facility was, rather surprisingly, nearly 60% larger in eyes perfused with 0.2% 4 
FAF-BSA in DBG compared to eyes perfused with DBG alone. More specifically, 5 
there was a statistical difference (p = 0.028, Welsh’s t-test) between eyes 6 
perfused with 0.2% FAF-BSA from Group A (0.0125 ± 0.0037 µL/min/mmHg, 7 
N = 6) compared to eyes perfused without FAF-BSA aggregated from Groups B 8 
and C (0.0078 ± 0.0025 µL/min/mmHg, N = 11). FAF-BSA was included as a 9 
carrier for S1P in the perfusion medium, following prior studies in human eyes20, 10 
and therefore FAF-BSA was excluded from experiments that did not contain S1P 11 
(i.e., all experiments from Group C and experiments from Group B examining 12 
JTE alone). We are not certain as to the cause of this difference, nor were there 13 
any obvious differences in the gender, age or genetic background of the mice 14 
that could explain this difference. Because elevated FAF-BSA would be expected 15 
to decrease (due to possible obstruction), rather than increase, outflow facility44, 16 
these data may indicate a potential trace contaminant carried from the FAF-BSA 17 
source (e.g., lipoprotein, phospholipid or lipopolysaccharide) that may itself 18 
increase facility. We observed that the effect of FAF-BSA on facility persisted 19 
through two different batches from the supplier (lot numbers 040M7715V and 20 
108k7425), suggesting a potential widespread, rather than batch-dependent, 21 
contaminant. Nevertheless, because our experiments used a paired perfusion 22 
approach, in which we compared the relative effects of selective receptor 23 
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agonists or antagonists diluted in otherwise identical perfusion solutions (both 1 
control and experimental), we conclude that the facility effects we observed were 2 
in fact due to drug treatment, and not to the presence or absence of FAF-BSA in 3 
the perfusion media.  4 
Data from the current study suggest that the fraction of unconventional 5 
outflow in mice may be significantly smaller than previously estimated3,4,6,11. We 6 
calculate the unconventional fraction of total outflow as 7 
 8 
Using the regression parameters from control eyes from Group C (perfused 9 
within 3 hrs post-enucleation without FAF-BSA; Fig. 4A) yields a relative 10 
contribution of 37.9 ± 15.6% unconventional to total outflow at 8 mmHg. In 11 
contrast, our previous work estimated that unconventional outflow represents 12 
66% of total outflow in C57BL/6 mice11. This difference is largely attributable to 13 
the 5-fold difference in FU between our current study (0.035 ± 0.025 µL/min; 14 
temperature-corrected; control eyes of Group C at 3 hrs) and our previous study 15 
(0.157 ± 0.026 µL/min)11, with a more modest difference observed in 16 
conventional outflow facility (0.0062 ± 0.0005 vs. 0.0091 ± 0.0012 17 
µL/min/mmHg11). We do not understand the reasons for such a large 18 
discrepancy in FU, but it may be related to differences in experimental 19 
techniques, and in particular the hydration of the eye, between the two studies. In 20 
the current study, the eye was covered with tissue paper that was kept moist by 21 
 
FU
C IOP( )+ FU
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regular drops of saline, while our previous study11 used regular drops of saline 1 
without tissue paper. It is thus possible that evaporation from the eye contributed 2 
to overestimation of FU in our previous study, and ongoing experiments are 3 
closely examining this hypothesis. Along these lines, a recent study10 has 4 
reported that the fraction of unconventional outflow in BALB/cJ mice (20.5%) is 5 
more consistent with the lower range of unconventional outflow estimated in 6 
human eyes (4 – 14%45), while unconventional outflow may be larger in other 7 
strains of mice (e.g., ~80% in NIH Swiss White mice3,4) and more consistent with 8 
the upper range of unconventional outflow estimated in human eyes (46-54%)46. 9 
This suggests that particular strains of mice (e.g., C57BL/6 or other strains that 10 
exhibit similar pharmacological behavior) may serve as better models for the 11 
physiology or pharmacology of IOP regulation as occurs within the conventional 12 
outflow pathway of human eyes. 13 
The conventional outflow pathway is sensitive to post-mortem 14 
degradation47, and enucleated whole human globes are routinely accepted for 15 
perfusion studies up to 24 hrs or longer after death. After 24 hrs post-enucleation 16 
and storage in DMEM at 4°C, the facility-increasing effect of 3,7-dithia PGE1 17 
remained statistically detectable in C57BL/6 mouse eyes, but only in the larger 18 
data set (unpaired set with 10 eyes) when conventional facility was measured as 19 
the slope of the flow rate-pressure relationship. When considering only perfusion 20 
data at individual pressures, the flow rate increase caused by 3,7-dithia PGE1 21 
failed to achieve statistical significance at 24 hrs (p ≥ 0.10). This suggests that a 22 
24 hr post-mortem delay likely represents an upper limit for detection of 23 
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pharmacological effects in ex vivo mouse eyes. More to this point, post-hoc 1 
analysis of conventional facility in DBG-perfused mouse eyes after 24 hrs 2 
(0.0087 µL/min/mmHg, temperature-corrected, from Group C) was approximately 3 
40% greater (p = 0.043; Welch’s t-test) than the facility measured in eyes within 3 4 
hrs after enucleation (0.0062 µL/min/mmHg, temperature-corrected, from Group 5 
C). This change in baseline facility explains why the relative facility increase 6 
following 3,7-dithia PGE1 after 24 hrs (38%) was nearly 3-fold less than that 7 
measured within 3 hrs (106%). Taken together, these data demonstrate that 8 
post-mortem changes occurring within 24 hrs can affect both conventional facility 9 
and the relative facility response to pharmacological compounds. We are not 10 
aware of any studies that have examined outflow facility as a function of post-11 
mortem time in human eyes, but if the post-mortem response of human and 12 
mouse eyes are similar, then these data suggest that there may be a 13 
considerable loss of sensitivity for detecting pharmacologically-induced changes 14 
in outflow facility using human eyes even at 24 hrs post-mortem. 15 
In conclusion, we demonstrate that conventional outflow facility in 16 
C57BL/6 mice mimics the pharmacological response of human eyes to PG-EP4 17 
and S1P receptor agonists that respectively increase and decrease outflow 18 
facility. These data strongly support the mouse eye (and possibly C57BL/6 or 19 
other strains) as a promising and robust model for the pharmacology of PG-EP4 20 
and S1P receptor activity on IOP regulation as occurs within the conventional 21 
outflow tract of human eyes, as well as for investigating the basic mechanisms of 22 
outflow resistance generation as relevant for glaucoma. 23 
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Figure Legends  1 
 2 
Figure 1: Data from Group A. Panel A) Typical perfusion tracings showing IOP 3 
(blue) and flow rate data for a control (solid black) and an S1P treated (dashed 4 
black) eye as a function of time (data taken from unpaired eyes). Yellow 5 
highlighted regions represent data used to calculate the average flow rate at 6 
each pressure level (4, 8, 15, 25, 8 mmHg). To enable flow traces from both 7 
control and experimental eyes to be seen on the same graph, flow rate tracings 8 
for the S1P treated eye were shifted by several minutes, and the pressure curve 9 
for the S1P-treated eye was omitted. Panel B) the average flow rate at each 10 
pressure level for all control (filled circles) and S1P treated eyes (open circles) 11 
from Group A. Bars are S.D. and lines represent the best-fit linear regressions to 12 
average data. FAF-BSA was included in the perfusion medium for all eyes 13 
represented in Panel B. Flow rate data are not temperature corrected. 14 
Figure 2: No obvious differences are observed in the histology of the iridocorneal 15 
angle from control (A) and S1P-treated (B) mouse eyes. AC, anterior chamber; 16 
TM, trabecular meshwork; SC, Schlemm’s canal; I, iris; C, cornea; S, sclera. Bars 17 
are 50 µm. The absence of giant vacuoles in the inner wall of Schlemm’s canal 18 
may reflect the fact that the eyes were fixed by immersion.  19 
Figure 3: Data from Group B. Panel A) Average flow rate at each pressure level 20 
for S1P (open circles) and S1P+JTE-013-treated eyes (filled circles). Controls for 21 
Panels A and B include eyes with and without vehicle formulations, as described 22 
in the text. Panel B) Average flow rate at each pressure level for S1P (open 23 
circles) and S1P+W146-treated eyes (filled squares). Panel C) Average flow rate 24 
at each pressure level for control (open diamonds) and JTE-treated eyes  without 25 
S1P (filled circles). Bars are S.D. and lines represent the best-fit linear regression 26 
to average data. FAF-BSA was included in the perfusion medium for all eyes 27 
represented in Panels A and B, but no FAF-BSA was included in the perfusion 28 
medium for Panel C. Flow rate data are not temperature corrected. 29 
Figure 4: Data from Group C. Average flow rate at each pressure level for 30 
control (filled circles) and 3,7-dithia PGE1 (open squares) treated eyes, within 3 31 
hrs (Panel A) or after 24 hrs post-mortem storage at 4°C (Panel B). Bars are S.D. 32 
and lines represent the best-fit linear regressions to average data. For Panels A 33 
and B, there was no FAF-BSA in the perfusion medium. Flow rate data are not 34 
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Figure 2: No obvious differences are observed in the histology of the iridocorneal 4 
angle from control (A) and S1P-treated (B) mouse eyes. AC, anterior chamber; 5 
TM, trabecular meshwork; SC, Schlemm’s canal; I, iris; C, cornea; S, sclera. Bars 6 
are 50 µm. The absence of giant vacuoles in the inner wall of Schlemm’s canal 7 
may reflect the fact that the eyes were fixed by immersion. 8 


































































te at each 
filled circle
rmulations































Figure 4: Data from Group C. Average flow rate at each pressure level for 4 
control (filled circles) and 3,7-dithia PGE1 (open squares) treated eyes, within 3 5 
hrs (Panel A) or after 24 hrs post-mortem storage at 4°C (Panel B). Bars are S.D. 6 
and lines represent the best-fit linear regressions to average data. For Panels A 7 
and B, there was no FAF-BSA in the perfusion medium. Flow rate data are not 8 
temperature corrected. 9 
  10 
Page 35 of 35 
 
Supplemental Figures 1 
 2 
Supplemental Figure 1: Confocal immunofluorescence microscopy of S1P 3 
receptor expression in angle tissues of the C57BL/6 mouse eye.  Slides 4 
containing frozen sections of mouse eyes (10 µm; embedded in OCT) were 5 
probed with polyclonal antibodies raised against peptides that correspond to 6 
carboxyl terminus of human S1P receptors 1 (sc-25489), 2 (sc-30024) and 3 (sc-7 
25491), but cross react with mouse.  Binding of primary antibodies to mouse 8 
tissues was visualized using goat anti-rabbit antibodies conjugated to Dylight that 9 
were excited and fluorescence signals digitally captured by a Leica SP5 confocal 10 
microscope.  Images from all sections were recorded during the same session 11 
using identical confocal settings. As a positive control for tissue quality and 12 
localization of Schlemm's canal endothelia (asterisks), slides containing mouse 13 
eye sections were probed with monoclonal antibodies that specifically recognize 14 
PECAM-1, followed by goat anti-mouse secondary antibodies conjugated to 15 
Dylight.  As a negative control, some slides containing mouse sections were 16 
probed only with goat anti-rabbit antibodies conjugated to Dylight (2). 17 
 18 
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